Delcath Systems Q1 2024 revenue jumps to $3.1M; raises center activation target to 20 by year-end

DELCATH SYSTEMS, INC.

2024-Q1 EPS reported -$0.45 revenue$3,139,000

Revenue $3.1M, up from $0.6M YoY, driven by HEPZATO KIT sales of $2.0M and CHEMOSAT of $1.1M.
Raised $7.0M in private placement; cash and investments total $27.2M at quarter end.
Appointed Dr. Martha S. Rook as COO; expanded center activation goal to 20 by end of 2024.
Received permanent J-code (J9248) and pass-through payment for HEPZATO KIT from CMS effective April 1.
SG&A rose to $8.8M from $4.2M due to commercial launch; R&D decreased to $3.7M.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

DELCATH SYSTEMS, INC. reported the first quarter ended March 31, 2024 results: revenue $3.1 million.

Period: the first quarter ended March 31, 2024
Revenue: $3.1 million
Result: reported results

Exact text from the filing

Total revenue for the quarter ended March 31, 2024 was $3.1 million compared to $0.6 million for the same period in the prior year from our sales of HEPZATO in the U.S. and CHEMOSAT in Europe.

View on SEC.gov

1047 earnings releases filed in the last 30 days. Browse all earnings releases →

DELCATH SYSTEMS, INC. filing history →

Source: SEC EDGAR

accession 0001628280-24-023065

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.